Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3596)	10/23/2018 3:49:59 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 3661

Believe it's RO6874281. Typo, either Wainwright or the fly.

To: Miljenko Zuanic who wrote (3596)	10/23/2018 4:40:46 PM
From: tuck	Read Replies (1) \| Respond to of 3661

Were you referring to BofA Merrill Lynch or Mechanism Of Action? In either case, the trial that read out at ESMO now has a combo arm with Tecentriq, a PD-1 drug, with or with out bevacizumab: Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) Some indications, such as RCC, are being tested by both companies. Cheers, Tuck